Dexcom (DXCM) Gross Profit (2010 - 2026)

Dexcom (DXCM) has 17 years of Gross Profit data on file, last reported at $750.3 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $750.3 million, up 27.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 20.2% YoY), and the FY2025 annual result was $2.8 billion, up 14.92% from the prior year.
• Gross Profit eased to $750.3 million in Q1 2026 per DXCM's latest filing, from $792.7 million in the prior quarter.
• Over five years, Gross Profit peaked at $792.7 million in Q4 2025 and troughed at $398.1 million in Q1 2022.
• A 5-year average of $597.8 million and a median of $593.8 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2026: Gross Profit slipped 4.73% in 2024, then grew 27.39% in 2026.
• A 5-year view of Gross Profit shows it stood at $541.3 million in 2022, then grew by 21.3% to $656.6 million in 2023, then slipped by 0.12% to $655.8 million in 2024, then gained by 20.88% to $792.7 million in 2025, then dropped by 5.35% to $750.3 million in 2026.
• Business Quant data shows DXCM's Gross Profit at $750.3 million in Q1 2026, $792.7 million in Q4 2025, and $731.4 million in Q3 2025.